Shuli Yi

Phase I study of A166, an antibody‒drug conjugate in advanced HER2-expressing solid tumours

Jian Zhang, Rujiao Liu, Shuiping Gao et al. · npj Breast Cancer · 2023 · 54 citations · Full text

Medicine, Oncology, Pharmacology +17

Therapeutic potential of an anti-HER2 single chain antibody–DM1 conjugates for the treatment of HER2-positive cancer

Hang Zhang, Yuxi Wang, Yangping Wu et al. · Signal Transduction and Targeted Therapy · 2017 · 44 citations · Full text

Pharmacy, Oncology, Pharmacology +17

Promiximab-duocarmycin, a new CD56 antibody-drug conjugates, is highly efficacious in small cell lung cancer xenograft models

Lin Yu, Ying Lu, Yuqin Yao et al. · Oncotarget · 2017 · 28 citations · Full text

Medicine, Oncology, Pharmacology +17

Phase I study of A166 in patients with HER2-expressing locally advanced or metastatic solid tumors.

Xichun Hu, Jian Zhang, Rujiao Liu et al. · Journal of Clinical Oncology · 2021 · 24 citations

Medicine, Oncology, Pharmacology +17

Clinical outcomes of metastatic breast cancer patients with triple-negative phenotype who received platinum-containing chemotherapy

Shuli Yi, Jieun Uhm, E. Cho et al. · Journal of Clinical Oncology · 2008 · 14 citations

Medicine, Oncology, Pharmacology +14